Literature DB >> 12072165

Adoption and implementation of new technologies in substance abuse treatment.

Paul M Roman1, J Aaron Johnson.   

Abstract

In addition to clinical outcomes, understanding the adoption and implementation of new treatment interventions is essential. This analysis was designed to assess the predictive utility of organization-level features in understanding the adoption and implementation of new technologies in substance abuse treatment. Naltrexone, which was found to be in current use in 44.1% of a national sample of 400 private substance abuse treatment centers, was selected as an appropriate sample technology for study. Adoption of naltrexone is significantly related to both the treatment center's age and its administrative leadership. Naltrexone adoption is also significantly associated with the percentage of the center's caseload covered by managed care programs and by the percentage of relapsers represented in the caseload. The analysis was less successful in predicting naltrexone implementation for either primary alcohol dependence or primary opiate addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072165     DOI: 10.1016/s0740-5472(02)00241-6

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  85 in total

Review 1.  Evidence-based practices for substance use disorders.

Authors:  Mark P McGovern; Kathleen M Carroll
Journal:  Psychiatr Clin North Am       Date:  2003-12

2.  Advancing recovery: implementing evidence-based treatment for substance use disorders at the systems level.

Authors:  Laura A Schmidt; Traci Rieckmann; Amanda Abraham; Todd Molfenter; Victor Capoccia; Paul Roman; David H Gustafson; Dennis McCarty
Journal:  J Stud Alcohol Drugs       Date:  2012-05       Impact factor: 2.582

3.  Assessing the utility of consumer surveys for improving the quality of behavioral health care services.

Authors:  J Randy Koch; Alison B Breland; Mary Nash; Karen Cropsey
Journal:  J Behav Health Serv Res       Date:  2011-04       Impact factor: 1.505

4.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

5.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

6.  Validation of the Implementation Leadership Scale (ILS) in Substance use Disorder Treatment Organizations.

Authors:  Gregory A Aarons; Mark G Ehrhart; Elisa M Torres; Natalie K Finn; Scott C Roesch
Journal:  J Subst Abuse Treat       Date:  2016-05-14

7.  Associations among state and local organizational contexts: Use of evidence-based practices in the criminal justice system.

Authors:  Craig E Henderson; Douglas W Young; Jill Farrell; Faye S Taxman
Journal:  Drug Alcohol Depend       Date:  2009-01-25       Impact factor: 4.492

8.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

9.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

10.  Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Authors:  Peter D Friedmann; Lan Jiang; Jeffrey A Alexander
Journal:  J Behav Health Serv Res       Date:  2009-03-19       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.